EWTX
Edgewise Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 1 ▲ Edgewise Therapeutics announced an asset purchase agreement to sell…
- Jul 1 ▼ 1 insider sell $7.9M at $39.41
- Jul 13 ▲ Edgewise Therapeutics completed the sale of its sevasemten muscular…
- Aug 6 Edgewise Therapeutics reported Q2 2026 net loss of $0.53/share, a 12…
- Aug 12 to Aug 13 ▼ 2 days of insider sells: $1.9M by 5 insiders, avg $43.73
- Sep 21 Trial readout: Results Pending: Sevasemten 10 mg (Phase 2), Completed 14d…
- Oct 12 Trial readout: T-90d Trial Readout: Sevasemten Dose 1 (Phase 2)
- Oct 16 William Blair initiates
- Oct 19 Trial readout: T-90d Trial Readout: Sevasemten Dose 1 (Phase 2)
- Oct 21 Trial readout: Results Pending: Sevasemten 10 mg (Phase 2), Completed 44d…
- Oct 26 Trial readout: T-90d Trial Readout: Sevasemten Dose 1 (Phase 2)
- Nov 10 ▼ 1 insider sell $201.8K at $45.43
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $10.0M.
- InstitutionsBULLISH
Q2 2026: 26 added (1 new), 12 trimmed or exited. Largest new: Adage Capital Partners Gp, L.L.C $18.8M.
- AnalystsBULLISH
17 of 19 rate it Buy or better. Median target $53.50 (+22%).
- EstimatesFALLING
Current-quarter EPS estimate −$0.379 → −$0.442 over 90 days. 2 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +8.0% to 12.70M shares. 9.6 days to cover, ≈11.6% of shares.
- TrendUPTREND
6% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | DOUBLED | $223.0M |
| BAKER BROS. ADVISORS LP | TRIM | $150.4M |
| Qube Research & Technologies Ltd | ADD | $50.9M |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | $33.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $32.0M |
| NORGES BANK | TRIM | $20.7M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | NEW | $18.8M |
| RAYMOND JAMES FINANCIAL INC | DOUBLED | $12.9M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is inside the target range. Median implies +22%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | Wedbush MAINTAIN | Outperform |
| Oct 16, 2026 | William Blair INITIATE | Outperform |
| Sep 21, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 20, 2026 | JP Morgan MAINTAIN | Overweight |
| Aug 11, 2026 | Goldman Sachs MAINTAIN | Neutral |
| Aug 6, 2026 | Wedbush MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Nofi Michael Chief Financial Officer Nov 10, 2026 | SELL | $201.8K |
Nofi Michael Chief Financial Officer Nov 10, 2026 | EXERCISE | 10,937 sh |
Fox Jonathan C Director Oct 1, 2026 | AWARD | 308 sh |
Donovan Joanne M. CMO Aug 13, 2026 | SELL | $126.7K |
KOCH KEVIN President and CEO Aug 12, 2026 | SELL | $361.3K |
MOORE JOHN R General Counsel Aug 12, 2026 | EXERCISE | 5,781 sh |
KOCH KEVIN President and CEO Aug 12, 2026 | SELL | $383.3K |
MOORE JOHN R General Counsel Aug 12, 2026 | SELL | $4.4K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.44 | -$0.60–-$0.25 | -15.5% | $0.00 |
| Next Q | -$0.44 | -$0.53–-$0.31 | +18.6% | $0.00 |
| Current FY | $7.66 | -$1.50–$9.29 | +454.7% | $0.00 |
| Next FY | -$1.89 | -$2.61–-$1.24 | -4.0% | $8.6M |
Short side
FINRA· Oct 30, 2026SecBot reports
14 filings · 2 bullish · 0 bearish · 1 mixed · 11 neutral- NEUTRAL 144Nov 16, 2026
Director Joanne M. Donovan filed a Form 144 notice of intent to sell 854 shares of Edgewise Therapeutics common stock, valued at approximately $39,224. The shares were acquired through the company's Employee Stock Purchase Plan on May 15, 2025.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Janus Henderson Group Ltd. filed an amended Schedule 13G reporting beneficial ownership of 7,298,521 shares of Edgewise Therapeutics common stock as of September 30, 2026, representing 6.7% of shares outstanding. This is a routine passive stake update filed after Edgewise reported Q3 results that…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 970,920 shares…
Fidelity's passive stake is unchanged at 0.9%, indicating no material conviction signal. The filing is routine and follows the Q3 earnings release. Monitor for any future 13D conversion or…
- NEUTRAL 8-KNov 4, 2026
Edgewise Therapeutics reported Q3 2026 net income of $1.166 billion ($9.65 diluted EPS), driven by…
The reported EPS is dominated by a one-time gain and does not reflect operating performance. Focus on the upcoming Phase 3 initiation for EDG-7500 and Phase 2 data for EDG-15400 as the next…
All EWTX filing & press-release reports (14)
- 144 reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 4, 2026
- INST-CLUSTER reportNov 2, 2026
- CLUSTER reportAug 14, 2026
- CLUSTER reportAug 14, 2026
- 8-K reportAug 6, 2026
- 8-K reportJul 13, 2026
- 8-K reportJun 1, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 23, 2026
- 144 reportMar 27, 2026
- 8-K reportFeb 26, 2026